Mirum Pharmaceuticals (MIRM) News Today → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free MIRM Stock Alerts $25.05 -0.86 (-3.32%) (As of 12:58 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conferencefinance.yahoo.com - May 7 at 8:18 PMMirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFICfinance.yahoo.com - May 7 at 10:17 AMMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Rating of "Buy" from Brokeragesamericanbankingnews.com - May 4 at 6:10 AMMirum Pharmaceuticals (MIRM) Set to Announce Quarterly Earnings on Wednesdaymarketbeat.com - May 2 at 10:17 AMMirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024businesswire.com - May 1 at 4:10 PMMirum Pharmaceuticals Inc (MIRM)investing.com - April 26 at 6:17 PMMirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week Low at $23.14marketbeat.com - April 25 at 3:44 PMMirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Valueseekingalpha.com - April 22 at 5:39 PMKnights of Columbus Asset Advisors LLC Grows Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - April 21 at 6:39 AMStifel starts Mirum at buy, cites IBATi drug potentialmsn.com - April 18 at 1:43 PMStifel Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Buy Recommendationmsn.com - April 17 at 9:44 PMStifel Nicolaus Initiates Coverage on Mirum Pharmaceuticals (NASDAQ:MIRM)marketbeat.com - April 17 at 3:51 PMBuy Rating Affirmed for Mirum Pharmaceuticals Amidst Strategic Positioning and Treatment Breakthroughsmarkets.businessinsider.com - April 17 at 6:43 AMBuy Rating Affirmed for Mirum Pharmaceuticals Amid Positive Clinical Trial Outlookmarkets.businessinsider.com - April 16 at 5:53 PMMirum Pharmaceuticals (NASDAQ:MIRM) Sets New 1-Year Low at $24.17marketbeat.com - April 15 at 10:57 AMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - April 10 at 9:30 PMMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of "Buy" by Analystsmarketbeat.com - April 9 at 4:10 AMVanguard Group Inc. Acquires 98,685 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - April 9 at 4:08 AMMirum Pharmaceuticals (NASDAQ:MIRM) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - April 2 at 12:13 PMMirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndromefinance.yahoo.com - April 2 at 9:42 AMMirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndromebusinesswire.com - April 2 at 8:30 AMEric Bjerkholt Purchases 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stockinsidertrades.com - March 28 at 8:46 AMEric Bjerkholt Acquires 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stockmarketbeat.com - March 27 at 9:29 PMMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $111,017.40 in Stockinsidertrades.com - March 26 at 4:44 AMMirum Pharmaceuticals Inc (MIRM) Insider Sells Sharesfinance.yahoo.com - March 26 at 4:07 AMMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich Sells 4,303 Sharesmarketbeat.com - March 25 at 9:31 PMLeerink Partnrs Equities Analysts Boost Earnings Estimates for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - March 20 at 6:39 AMMirum Pharmaceuticals COO sells over $28k in company stockinvesting.com - March 20 at 5:21 AMLeerink Partnrs Analysts Reduce Earnings Estimates for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - March 19 at 6:55 AMEric Bjerkholt Buys 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stockinsidertrades.com - March 19 at 5:38 AMCracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticalsmarkets.businessinsider.com - March 18 at 6:15 PMJMP Securities Boosts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $72.00marketbeat.com - March 18 at 5:59 PMMirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Down 3.9%marketbeat.com - March 15 at 3:34 PMMIRM Mar 2024 40.000 callca.finance.yahoo.com - March 15 at 10:56 AMBuy Rating Affirmed for Mirum Pharmaceuticals Following FDA Approval and Promising Pipeline Developmentsmarkets.businessinsider.com - March 15 at 10:56 AMMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Buy" by Analystsmarketbeat.com - March 15 at 6:41 AMFDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategymsn.com - March 14 at 5:34 PMMirum Pharmaceuticals Gets Additional FDA Approval for Livmarlimarketwatch.com - March 14 at 12:33 PMBuy Rating Affirmed for Mirum Pharmaceuticals Following FDA Approval and Positive Revenue Outlookmarkets.businessinsider.com - March 14 at 7:32 AM3 Best Stocks to Buy Now, 3/14/2024, According to Top Analystsmsn.com - March 14 at 7:32 AMMirum gains as FDA accepts label expansion of liver disease drugmsn.com - March 14 at 7:32 AMUS FDA approves expanded use of Mirum's liver disease drugreuters.com - March 13 at 8:14 PMMirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasisfinance.yahoo.com - March 13 at 8:14 PMMirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasisbusinesswire.com - March 13 at 6:00 PMPolar Capital Holdings Plc Increases Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - March 12 at 10:35 AMMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - March 8 at 7:30 PMAdage Capital Partners GP L.L.C. Acquires New Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - March 7 at 7:44 AMMirum Pharmaceuticals: Advancing On Several Key Frontsseekingalpha.com - March 5 at 5:29 AMArdsley Advisory Partners LP Takes Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)marketbeat.com - March 3 at 11:16 AMMirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 1 at 6:57 PM Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. MIRM Media Mentions By Week MIRM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIRM News Sentiment▼0.600.38▲Average Medical News Sentiment MIRM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIRM Articles This Week▼53▲MIRM Articles Average Week Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Collegium Pharmaceutical News Today MannKind News Today Pacira BioSciences News Today Spyre Therapeutics News Today Verona Pharma News Today AbCellera Biologics News Today Belite Bio News Today Prothena News Today Gyre Therapeutics News Today Ironwood Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIRM) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorFidelity, Bezos, Goldman Bet Big on Tiny BiotechBehind the MarketsAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
